Alzamend Neuro Inc Sustainability Reports
A clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. The company's pipeline includes product candidates aimed at addressing Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 549300W6G6EUO4ZRIB82
FIGI: BBG00ZMXG7N7
5 reports from 2020 to 2025
